Stem cell transplantation in Hodgkin lymphoma

Area of Science:

• Oncology
• Hematology

Background:

• Hematopoietic stem cell transplantation (HSCT) is a key treatment for relapsed or refractory Hodgkin lymphoma.
• Patient outcomes improve with demonstrated sensitivity to salvage chemotherapy prior to HSCT.

Purpose of the Study:

• To review the efficacy and considerations of hematopoietic stem cell transplantation in Hodgkin lymphoma.
• To discuss treatment options for patients relapsing post-transplantation or with refractory disease.

Main Methods:

• Review of current literature and treatment strategies for Hodgkin lymphoma.
• Analysis of outcomes for autologous and allogeneic stem cell transplantation.
• Discussion of salvage chemotherapy, radiotherapy, and novel therapeutic approaches.

Main Results:

• Autologous HSCT can cure approximately 50% of patients.
• Sequential high-dose therapy is being explored to enhance outcomes.
• Reduced-intensity allogeneic transplantation shows promise for young relapsed patients.
• Lifelong surveillance is crucial for monitoring late toxicities like secondary malignancies.

Conclusions:

• Hematopoietic stem cell transplantation is an established, yet not universally curative, treatment for Hodgkin lymphoma.
• Salvage chemotherapy sensitivity is a critical prognostic factor.
• For patients with multiple relapses or refractory disease, novel therapeutic strategies are essential.